Effect of Amlodipine/Nebivolol combination therapy on central BP and PWV compared to Amlodipine/Valsartan combination therapy.

Autor: Sultan EM; Cardiology Department, Beni-Suef University Hospital, Beni-Suef City, 62511, Egypt. Zahraaesmat.713@gmail.com., Rabea H; Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef City, 62511, Egypt., Elberry AA; Department of Pharmacy Practice, Pharmacy Program, Batterjee Medical College, Jeddah, 21442, Saudi Arabia., Mahmoud HB; Beni-Suef University Hospital, Beni-Suef City, 62511, Egypt.
Jazyk: angličtina
Zdroj: The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology [Egypt Heart J] 2022 Mar 14; Vol. 74 (1), pp. 15. Date of Electronic Publication: 2022 Mar 14.
DOI: 10.1186/s43044-022-00254-0
Abstrakt: Background: Pulse wave velocity (PWV) and central blood pressure (CBP) have been intoduced into managment of hypertensive patients. PWV is positively correlated with arterial wall stiffness while central aortic pressure becomes better predictor of cardiovascular outcome than peripheral pressure. Reduction in CBP provides protective properties against subclinical organ damage. This work aims to investigate the effect of a new combination therapy of Amlodipine/Nebivolol (A/N) on central BP, peripheral BP and PWV. The results of using this combination will be compared to the well-established fixed-dose combination of Amlodipine/Valsartan (A/V). The study conducted between October 2018 and August 2020. One hundred and two hypertensive patients were assigned for Amlodipine 10 mg/Valsartan 160 mg combination therapy (A/V, n = 52) or Amlodipine 10 mg/Nebivolol 5 mg combination therapy (A/N, n = 50) by simple 1:1 randomization. Office, central blood pressure and PWV were measured on first (0 week), second (4-8 weeks) and third visit (10-12). Difference in BP (in each arm and between arms) was calculated along all visits.
Results: No statistical significant difference was found between A/V and A/N regarding age, gender, BMI and CV history. OBP, CBP and PWV were significantly reduced in each arm, but no differences were found when comparing both arm results to each other. Recorded side effects were insignificant.
Conclusions: The new combination therapy Amlodipine/Nebivolol (A/N) affords a significant reduction in CBP, PBP and PWV with minor and tolerable side effects. It has provided comparable results to Amlodipine/Valsartan (A/V) combination therapy.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: